Jennifer W Lee1, Jonathan M Davis. 1. The Floating Hospital for Children at Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.
Abstract
PURPOSE OF REVIEW: This review will examine the unique susceptibility of premature infants to oxidative stress, the role of reactive oxygen species (ROS) in the pathogenesis of common disorders of the preterm infant, and potential for therapeutic interventions using enzymatic and/or nonenzymatic antioxidants. RECENT FINDINGS: Oxidative stress is caused by an imbalance between the production of ROS and the ability to detoxify them with the help of antioxidants. The premature infant is especially susceptible to ROS-induced damage because of inadequate antioxidant stores at birth, as well as impaired upregulation in response to oxidant stress. Thus, the premature infant is at increased risk for the development of ROS-induced diseases of the newborn, such as bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, and periventricular leukomalacia. SUMMARY: Potential therapies for ROS-induced disease include both enzymatic and nonenzymatic antioxidant preparations. More research is required to determine the beneficial effects of supplemental antioxidant therapy.
PURPOSE OF REVIEW: This review will examine the unique susceptibility of premature infants to oxidative stress, the role of reactive oxygen species (ROS) in the pathogenesis of common disorders of the preterm infant, and potential for therapeutic interventions using enzymatic and/or nonenzymatic antioxidants. RECENT FINDINGS:Oxidative stress is caused by an imbalance between the production of ROS and the ability to detoxify them with the help of antioxidants. The premature infant is especially susceptible to ROS-induced damage because of inadequate antioxidant stores at birth, as well as impaired upregulation in response to oxidant stress. Thus, the premature infant is at increased risk for the development of ROS-induced diseases of the newborn, such as bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, and periventricular leukomalacia. SUMMARY: Potential therapies for ROS-induced disease include both enzymatic and nonenzymatic antioxidant preparations. More research is required to determine the beneficial effects of supplemental antioxidant therapy.
Authors: Mohamed N Ahmed; Hagir B Suliman; Rodney J Folz; Eva Nozik-Grayck; Maria L Golson; S Nicholas Mason; Richard L Auten Journal: Am J Respir Crit Care Med Date: 2002-10-03 Impact factor: 21.405
Authors: Manjeet K Paintlia; Ajaib S Paintlia; Miguel A Contreras; Inderjit Singh; Avtar K Singh Journal: Exp Neurol Date: 2007-12-23 Impact factor: 5.330
Authors: Philip L Ballard; William E Truog; Jeffrey D Merrill; Andrew Gow; Michael Posencheg; Sergio G Golombek; Lance A Parton; Xianqun Luan; Avital Cnaan; Roberta A Ballard Journal: Pediatrics Date: 2008-03 Impact factor: 7.124
Authors: George D Georgeson; Barnabás J Szony; Károly Streitman; Ilona Sz Varga; Attila Kovács; László Kovács; Aranka László Journal: Eur J Obstet Gynecol Reprod Biol Date: 2002-07-10 Impact factor: 2.435
Authors: Joseph M Collaco; Lewis H Romer; Bridget D Stuart; John D Coulson; Allen D Everett; Edward E Lawson; Joel I Brenner; Anna T Brown; Melanie K Nies; Priya Sekar; Lawrence M Nogee; Sharon A McGrath-Morrow Journal: Pediatr Pulmonol Date: 2012-07-06
Authors: Qian Li; Stephanie B Wall; Changchun Ren; Markus Velten; Cynthia L Hill; Morgan L Locy; Lynette K Rogers; Trent E Tipple Journal: Am J Respir Cell Mol Biol Date: 2016-09 Impact factor: 6.914
Authors: Cuneyt Tayman; Alparslan Tonbul; Aydın Kosus; Ibrahim Murat Hirfanoglu; Hacer Haltas; Sema Uysal; Mustafa Mansur Tatli; Fatih Andiran Journal: Pediatr Surg Int Date: 2011-06-28 Impact factor: 1.827